(People's Daily health client Tan Qixin)
According to the incomplete statistics of the People's Daily health client, this week (January 3-7) a total of 25 investment and financing incidents occurred in the national pharmaceutical field, and the enterprises that obtained financing involved tumor new drug development, cancer early screening, Alzheimer's disease early screening detection, innovative medical devices and other fields, of which Jiayue Pharmaceutical, Yikun Biological, New Element Pharmaceutical and other pharmaceutical companies have obtained more than 100 million yuan in financing.
Jing Egg Bio completed nearly 100 million yuan Pre-A round of financing
On January 7, Shenzhen Jing egg Biotech announced that it has completed a Pre-A round of financing of nearly 100 million yuan. This round of financing is led by Longmen Capital, Hongzhao Group, Zijingang Capital, Chengdu Pilot, Yueke Finance, Zhongcheng New Industry and Riemann Conjecture and other institutions followed, and the previous round of leading investor Tiantu Investment continued to increase investment.
This round of financing funds will be mainly used to build the world's top ion channel and GPCR drug screening platform, focus on promoting chronic kidney disease drugs to clinical phase I; new membrane protein deconstruction and drug screening, reserve new drug variety pipelines; introduce core team personnel and the daily operation of the company.
Founded in 2019, Jing Egg Bio is committed to the research and development of innovative drug products for membrane proteins (including ion channels and GPCRs) for major diseases such as chronic kidney disease and psychiatric diseases.
Yimufeng Biotech obtained a series A financing of 100 million yuan
On January 7, Shanghai Yimufeng Biotech announced that it has recently completed a round of financing of 100 million yuan. This round of financing is led by Delian Capital, followed by Yuanlifang Capital and Luojia Fangyuan, and the old shareholder Daoyuan Capital continues to invest additionally. The funds raised are mainly used for the company's multiple IIT clinical studies and the Sino-US filing of the first new drug research application project.
Yi Mufeng is an innovative enterprise that uses the immune cell therapy technology platform and combines clinical innovation to develop new solid tumor treatment drugs, and launched operations in Zhangjiang, Shanghai in September 2020.
AuriBio completed over 100 million yuan of B round financing
On January 7, Hangzhou Aorui Biology announced the completion of more than 100 million yuan of B round financing, strategic investment by the famous IVD listed company Heatscape Biology, and the funds raised in this round will be mainly used for the clinical and registration of the company's liver cancer early screening and early diagnosis products, as well as the research and development of a variety of follow-up product pipelines.
Founded in 2018, the company broke through the technical barriers of multi-omics detection product development based on its original patented technology and algorithm, and developed a series of single and multi-cancer products with unique value. Among them, liver cancer is the earliest product field for the company to enter the commercialization at this stage.
Jiayue Pharmaceutical completed nearly 200 million yuan of B+ round financing
On January 6, Jiayue Pharmaceutical announced the completion of nearly 200 million yuan of B+ round of financing, led by Guanzi Venture Capital, and the old shareholders SDIC Venture Capital, Sequoia Capital China Fund and Lingcheng Venture Capital continued to follow suit. This is the second round of financing completed by Jiayue Pharmaceutical in the six months after the completion of the B round of financing in July 2021, and this round of financing will be used to promote the mid- and late-stage clinical projects of the company's multiple innovative drug pipelines.
Driven by translational medicine and clinical medicine, Jiayue Pharmaceutical has a team of innovative drugs that have participated in the development of multiple FIC/BIC drugs for many years, focusing on the development of oncology and autoimmunity, metabolic and infectious diseases.
New Element Pharmaceutical completed a series C financing of more than 300 million yuan
On January 5, Jiangsu New Element Pharmaceutical announced that it has recently completed a series C financing of more than 300 million yuan, and the funds of this series of C financing will be mainly used to complete the global Phase 3 clinical trial of ABP-671, as well as the preclinical and early clinical research of other pipeline products. Previously, New Element Pharmaceutical has completed a total of hundreds of millions of yuan in financing.
Jiangsu New Element Pharmaceutical is mainly engaged in the research and development of metabolic diseases and anti-cancer innovative drugs, with a variety of project portfolios, of which abstop-671, an innovative anti-gout drug in the field of metabolic diseases, has completed Phase 1 clinical trials in the United States and is carrying out Phase 2 clinical research. The company's pipeline products also include innovative drugs in the treatment of NASH and anti-tumor fields, some of which are about to enter preclinical or clinical research.
Krygen completed a $60 million Series B funding round
On January 5, Suzhou Kri Gene Biotech announced the completion of a $60 million Series B financing. This round of financing was led by the strategic investor Shangjun Investment, followed by Yuanhe Holdings, Blue Ocean Capital, Qiming Venture Capital and other institutions, and China Renaissance Capital served as the exclusive financial advisor. This round of financing will be mainly used to accelerate the clinical development of Clarion's therapeutic products in blood and solid tumor cells, and to promote the development and international cooperation of innovative serotype screening and gene editing products based on AAV virus.
Founded in 2016, Suzhou Kerui Gene Biotechnology Co., Ltd. is an innovative gene cell therapy company that has raised nearly $100 million so far.
Tianjun Yuansheng Bio received millions of yuan of angel round financing
On January 5, Tianjun Yuansheng Biotech recently announced that it has obtained a multi-million yuan angel round financing from strategic investor Guogao Biotech, with Meiyu Capital as the financial advisor; this round of financing is mainly used to accelerate the progress of product research and development.
Tianjun Yuansheng Bio focuses on the research and development of Alzheimer's disease early screening detection products, the products are mainly used for the early diagnosis and screening of AD, so that the trend of patients with AD can be predicted about 15 to 20 years in advance, and the core products include clinical detection equipment and reagents for AD peripheral blood, and laboratory-level diagnosis has been realized.
Sai Lan Pharmaceutical completed nearly 200 million yuan of Series A financing
On January 4, Sai Lan Pharmaceutical announced that it has recently completed a Series A financing of nearly 200 million yuan. This round of financing is jointly led by Zeyue Capital and CDH VGC, with Kaitai Capital, Dawu Venture Capital and SAIC Hengxu Capital, and Haoyi Capital acting as the exclusive financial adviser for this round.
It is reported that this round of financing will be used to accelerate the development of a number of epigenetic targeted new drugs on the Sailan Pharmaceutical pipeline to promote clinical development, and further build the Epigenetics TECHNOLOGY research and development platform of Sailan Pharmaceutical EpigenPLUS.
Hui therapy Biotech received nearly RMB 100 million in seed round investment
On January 3, Huihe Biotech announced that it has received a seed round investment of nearly 100 million yuan, invested by Sequoia China, Gimpo Health and Huiding Investment.
Suzhou Hui therapy Biomedical Technology Co., Ltd. is a high-tech enterprise engaged in the industrialization of comprehensive nucleic acid drugs. The company's business covers mRNA drug research and development and production, clinical trial design, data analysis and other fields, focusing on the development of infectious disease vaccines, tumor vaccines, cell therapy, protein substitution and so on based on mRNA technology. Around the new mRNA delivery preparation CLS system, the company is committed to the development of mRNA drug technology production platform with independent intellectual property rights in China.
Yikun Biotech completed a $100 million Series B financing
On January 6, Yikun Bio has completed a $100 million B round of financing, which was jointly led by Sequoia China and Morningside Venture Capital, and followed by Yuanhe Holdings. The original shareholders, Eli Lilly Asia Fund and Perkin Elmer Venture Capital, continued to raise bets. Haoyue Capital acted as the exclusive financial advisor for this round of financing.
Founded in 2019, Yikun Bio is positioned as a global platform-based innovative in vitro diagnostic product and service provider, focusing on the field of oncology, maternal and infant health and chronic diseases using innovative technology platforms such as clinical mass spectrometry, panoramic pathology, molecular diagnosis to expand the domestic market; and adopting cooperative research and development, investment and mergers and acquisitions to lay out platforms such as chemiluminescence and POCT to expand overseas emerging markets.
